Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: Inflectra | Statement: [Remicade, hasBiosimilar, Inflectra]

Target entity: Inflectra
Context triple: [Remicade, hasBiosimilar, Inflectra]

• A. Verzenio
  Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
• B. Darzalex
  Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
• C. Alimta
  Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
• D. Vumerity
  Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
• E. Anpezan
  Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"

Entity: Inflectra
Triple: [Remicade, hasBiosimilar, Inflectra]

Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.

Target entity: Inflectra
Target entity description: Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.

• A. Verzenio
  Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
• B. Darzalex
  Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
• C. Alimta
  Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
• D. Vumerity
  Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
• E. Anpezan
  Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
• F. None of above. chosen

Target predicate: hasBiosimilar
Context triple: [Remicade, hasBiosimilar, Inflectra]

• A. isPegylated
  Indicates that a molecule, typically a drug or therapeutic agent, has been chemically modified by the attachment of polyethylene glycol (PEG) chains.
• B. isExtendedReleaseFormulationOf
  Indicates that one pharmaceutical formulation is an extended-release version of another, designed to release the active ingredient more slowly over time.
• C. hasTargetDisease
  Indicates that an entity (such as a treatment, study, or intervention) is directed toward, intended to affect, or primarily concerned with a specified disease.
• D. FDAApprovalType
  Indicates the specific regulatory pathway or category under which a product has been approved by the U.S. Food and Drug Administration.
• E. hasRegulatoryApproval
  Indicates that an entity has received formal authorization or clearance from a relevant regulatory authority to operate, be sold, or be used in a specified context.
• F. None of above. chosen